The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology
Open accessAbstract
Background Atopic dermatitis (AD) is the most common inflammatory disease. Evolving disease models link changes in epidermal growth and differentiation to Th2/Th22 cytokine activation. However, these models have not been tested by in-vivo suppression of T-cell cytokines. CsA is an immune-suppressant highly effective for severe disease, but its mechanism in AD skin lesions has not been studied. Objective To establish the ability of a systemic immune-suppressant to modulate immune and epidermal alterations that form the pathogenic disease phenotype, and to correlate changes with clinical improvement. Methods CsA effects on AD skin pathology were evaluated using geneexpression and immunohistochemistry studies in baseline, week 2 and 12 lesional and non-lesional biopsies from 19 patients treated with 5 mg/kg/d CsA for 12 weeks. Results After 2 and 12 weeks of treatment, we observed significant reductions of 51% and 72%, respectively, in Scoring of AD/SCORAD. Clinical improvements were associated with significant gene expression changes in lesional but also non-lesional skin, particularly reductions of Th2-, Th22-, and some Th17-related molecules (i.e IL-13, IL-22, CCL17, S100As, elafin/PI3), and modulation of epidermal hyperplasia and differentiation measures. Conclusions This is the first study that establishes a relationship between cytokine activation and molecular epidermal alterations as well as correlations between disease biomarkers in the skin and clinical improvement. The reversal of the molecular phenotype with CsA and the associated biomarkers can serve as a reference for the successful modulation of tissue inflammation with specific immune-antagonists in future studies, contributing to the understanding of the specific cytokines involved in epidermal pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.041 · Cited by 627 · cited 1×
“IL-22 has been linked to many aspects of epidermal pathology in patients with AD, including inhibition of epidermal differentiation, induction of hyperplasia, and upregulation of S100s, and has been strongly correlated with disease activity.(33,40,46) IL-4 and IL-13 have been reported to inhibit differentiation, produ…”
Self-citationTh2 Cytokines Act on S100/A11 to Downregulate Keratinocyte Differentiation
Howell, M. D., Fairchild, H. R., Kim, B. E., Bin, L., Boguniewicz, M., Redzic, J. S., Hansen, K. C., & Leung, D. Y. M. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.74 · Cited by 224
Epidermal Barrier in Atopic Dermatitis
Kim, B. E., & Leung, D. Y. (2012) · Allergy, Asthma and Immunology Research · doi:10.4168/aair.2012.4.1.12 · Cited by 114 · cited 2×
“However, the relative roles of the immune and barrier elements in disease pathogenesis and the extent to which their modulation is correlated with clinical improvement are not yet known.(5-10) Cyclosporine (CsA) is a potent immunosuppressant that acts primarily on T cells by inhibiting calcineurin and thus signal tran…”
Cited by
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Self-citationNoda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Self-citationCellular and molecular immunologic mechanisms in patients with atopic dermatitis
Werfel, T., Allam, J.-P., Biedermann, T., Eyerich, K., Gilles, S., Guttman-Yassky, E., Hoetzenecker, W., Knol, E., Simon, H.-U., Wollenberg, A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.010 · Cited by 594
Self-citationHamilton, J. D., Suárez-Fariñas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 469
Self-citation
Metadata
- Authors
- Khattri, S., Shemer, A., Rozenblit, M., Dhingra, N., Czarnowicki, T., Finney, R., Gilleaudeau, P., Sullivan-Whalen, M., Zheng, X., Xu, H., Cardinale, I., de Guzman Strong, C., Gonzalez, J., Suárez-Fariñas, M., Krueger, J. G., & Guttman-Yassky, E.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2014-06
- Volume
- 133
- Issue
- 6
- Pages
- 1626-1634
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2062276423
- Cited by
- 180
- References
- 3
- FWCI
- 20.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. https://app.cochat.ai/papers/10.1016/j.jaci.2014.03.003
- The paper
- Khattri, S., Shemer, A., Rozenblit, M., Dhingra, N., Czarnowicki, T., Finney, R., Gilleaudeau, P., Sullivan-Whalen, M., Zheng, X., Xu, H., Cardinale, I., de Guzman Strong, C., Gonzalez, J., Suárez-Fariñas, M., Krueger, J. G., & Guttman-Yassky, E. (2014). Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2014.03.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.